About Targeted Medical Pharma


Elizabeth Charuvastra

Elizabeth Charuvastra RN
Executive Chairman and Director of Regulatory Affairs and Compliance

Elizabeth Charuvastra was Executive Chairman of the Board of Directors and Director of Regulatory Affairs and Compliance. Ms. Charuvastra was founder and President of Beverly Glen Medical Systems, a California based national cardiac monitoring company from 1990 to 1999. Under Ms. Charuvastra's direction, Beverly Glen Medical Systems developed new technologies in high resolution continuous EKG (Holter) monitoring. This innovative testing has been used to assess the safety of new pharmaceutical agents during the FDA approval process and to assess autonomic nervous system functioning. The technology is also used by the Company for objective, quantitative diagnostic testing of cardiac and autonomic nervous system function in drug safety studies. Ms. Charuvastra authored a number of publications on long term Electrocardiography, measurement of the QT interval and relation to ventricular arrhythmias. More recently published articles include the results of clinical trials on amino acid based therapeutic agents.

William Shell M.D.

William Shell M.D.
Board Member, CEO and Chief Scientific Officer

William Shell M.D. is Board Member, CEO, and Chief Scientific Officer. Dr. Shell is a board certified cardiologist and inventor possessing multiple United States patents. Dr. Shell attended the University of Michigan Medical School and graduated in June 1967.  Dr. Shell was one of the first students chosen by the Michigan Heart Association to train in the cardiovascular division of University Hospital of University of Michigan.  He published the first American paper on the syndrome now known as Mitral Valve Prolapse, which demonstrated the genetic nature of this malady. Following his residency at the University of Michigan, Dr. Shell began a National Institutes of Health (NIH) Special Fellowship to study cardiology under Dr. Eugene Braunwald at the University of California San Diego. During his fellowship, Dr. Shell was a member of the team credited with discovering the cardio specific enzyme CK-MB.  A diagnostic test for the presence of the CK-MB enzyme is now the clinical foundation for the detection and treatment of heart attacks.  Dr. Shell and his colleagues published a total of 44 papers in medical journals on this body of work between 1969 and 1974.

Dr. Shell joined the United States Air Force following his fellowship.  The first months of his military service were spent in the American Soviet Exchange Program as the first American physician representing the National Institutes of Health and the American government in Moscow.  Several publications emanated from Dr. Shell's work in the Soviet Union, including early biochemical work that defined the relationship between heart cell growth and creatine. In addition, he and his Soviet colleagues performed clinical trials which led to the discontinuation of digitalis as a treatment of heart attacks. These studies lead to the early examination of reperfusion as part of the treatment of heart attacks. Upon his return to the United States, Dr. Shell served as the director of the coronary care unit at Keesler Air Force Base in Mississippi, where he supervised the construction of the first modern coronary care unit for the United States Air Force, which became the model for future units.  Dr. Shell was awarded a Presidential Citation by President Richard Nixon for his work in the American Soviet Exchange Program and his administrative work creating the coronary care unit at Keesler.

Following his discharge from the Air Force, Dr. Shell returned to Los Angeles and joined the cardiology staff at Cedars of Lebanon Hospital and Mount Sinai Hospital.  During his tenure, he planned, directed and implemented the merger of the coronary care unit at Cedars of Lebanon and Mount Sinai Hospital to what is now known as Cedars-Sinai Medical Center in Los Angeles, California.  Dr. Shell was also Director of the Cardiac Catheterization Laboratory and Director of Cardiac Rehabilitation.  In addition, he participated in the planning, funding and administration of NIH grants and managed a biochemistry research laboratory at Cedars-Sinai Medical Center.  Dr. Shell also was given teaching responsibilities at both Cedars-Sinai and the University of California at Los Angeles, where he obtained the title of Associate Professor of Medicine in Residence.

In 1989, Dr. Shell, along with Ms. Elizabeth Charuvastra, founded Beverly Glen Medical Systems, a cardiac diagnostic service company.  Dr. Shell served as the chief scientific officer and chief medical officer. The technology that was developed at this company resulted in two patents that allow for the measurement of autonomic nervous system activity and measurements of the QT interval on 24-hour electrocardiograms.  The technology has been used by the pharmaceutical industry in establishing safety standards for new drugs, by the Veterans Administration to establish that the Gulf War Syndrome is a form of nervous system dysfunction, and by the Environmental Protection Agency and other environmental groups to examine the effects of environmental toxins on the brain and other parts of the autonomic nervous system.

In 1991, Dr. Shell founded and served as chairman and chief executive officer of SeeShell Biotechnology, which merged with a company called Interactive Principals, which in turn merged into Interactive Medical Technologies, Inc. (IMT), whose stock was quoted on the Over the Counter Bulletin Board.   Dr. Shell relinquished the daily CEO role and retained the title of Chairman of the Board of Directors until 1995. Dr. Shell is the author of more than 150 scientific articles published in peer reviewed journals.

Kim Giffoni
Executive Vice President of Foreign Sales and Investor Relations

Kim Giffoni is our Executive Vice President of Foreign Sales and Investor Relations. Mr. Giffoni is a founder of TRGM and served as President and Chief Operating Officer and a director of TRGM from December 1999 to December 2010. Since December 2010, Mr. Giffoni has served as Executive Vice President of Foreign Sales and Investor Relations of TRGM. Prior to assuming his current responsibilities, from April 1996 to May 1999, Mr. Giffoni served as president of NutraCorp Scientific, Inc., a dietary supplement company marketing and selling nutritional products worldwide. From January 1983 to March 1996, Mr. Giffoni founded and served as president of Giffoni Development Company. Under Mr. Giffoni's direction the company profitability developed and sold multi-million dollar residences in Southern California. From 1980 through 1983 Mr. Giffoni served as an advertising manager of Herald Community Newspapers supervising advertising insert flow into fifteen local newspapers throughout Southern California. Prior to working for the Los Angeles based Herald Community Newspapers, from 1972 through 1979, Mr. Giffoni served as advertising director of the Las Virgines Enterprise Newspaper Group and co-founded the weekly newspaper Malibu Surfside News. Mr. Giffoni earned a Bachelor of Arts in Communications from California State University at Northridge. Mr. Giffoni is a former professional baseball player for the Kansas City Royals Professional Baseball Club and is a commercially-rated helicopter pilot.